Therapeutic Drug Monitoring Market Segmentation:
Type Segment Analysis
In the type segment, immunoassay leads the therapeutic drug monitoring market and is expected to hold the market share of 38.2% by 2037. The market is mainly driven by the automation capability, cost efficiency, and wide applicability across high-volume clinical laboratories. Their massive growth time makes them ideal for routine drug monitoring and antiepileptics, immunosuppressants, and antipsychotics. Further, the report of the U.S. Food and Drug Administration states that the automated immunoassay platforms meet FDA 510(k) standards for clearance and are known as the gold standard for several TDM applications. Their high throughput enables scalability across centralized testing centers and tertiary hospitals.
End User Segment Analysis
Under the end user segment, hospital laboratories are the dominant segment is expected to hold the therapeutic drug monitoring market share of 35.7% by 2037. This rise is especially due to the increased admissions in the hospitals for chronic disease conditions, increasing ICU drug administration, and the rise in therapeutic complexity of treatments, including chemotherapy and transplant medications. As per the Agency for Healthcare Research and Quality, almost 60.8% of the patients in the hospitals in the U.S. are on medications necessitating dose adjustment. Hospitals are investing more in real-time TDM integration for better therapeutic outcomes in home LC-MS systems.
Our in-depth analysis of the global therapeutic drug monitoring market includes the following segments:
|
Segment |
Subsegment |
|
Type |
|
|
Drug Class |
|
|
End user |
|
